

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> : <b>C07K 14/205, A61K 38/42 // C12N 15/12</b>		<b>A1</b>	(11) International Publication Number: <b>WO 97/15591</b>
			(43) International Publication Date: <b>1 May 1997 (01.05.97)</b>
(21) International Application Number: <b>PCT/US96/16934</b>			(74) Agents: <b>BROWN, Theresa, A.; Somatogen, Inc., Suite FD-1, 2545 Central Avenue, Boulder, CO 80301 (US) et al.</b>
(22) International Filing Date: <b>23 October 1996 (23.10.96)</b>			
(30) Priority Data: <b>60/006,020</b> <b>23 October 1995 (23.10.95)</b> <b>US</b>			(81) Designated States: <b>AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</b>
(60) Parent Application or Grant (63) Related by Continuation <b>US</b> <b>60/006,020 (CIP)</b> <b>Filed on</b> <b>23 October 1995 (23.10.95)</b>			<b>Published</b> <i>With international search report.</i>
(71) Applicant (for all designated States except US): <b>RICE UNIVERSITY [US/US]; Institute of Bioscience &amp; Bioengineering, 6100 South Main, Houston, TX 77005 (US).</b>			
(72) Inventors; and (75) Inventors/Applicants (for US only): <b>OLSON, John, S. [US/US]; 4407 Lymbar, Houston, TX 77096-4418 (US). WHITAKER, Timothy, L. [US/US]; Apartment 720, 5303 Hamilton Wolf Road, San Antonio, TX 78229 (US). HARGROVE, Mark, S. [US/US]; 3311 Elmridge Drive, Houston, TX 77025 (US).</b>			
(54) Title: <b>HEMOGLOBIN MUTANTS THAT REDUCE HEME LOSS</b>			
(57) Abstract <p>The present invention relates to methods of reducing heme loss in hemoglobins to produce stability and improve expression yield of hemoglobins, particularly recombinant hemoglobins. Such methods are accomplished by introducing mutations in the alpha or beta subunits of hemoglobins to increase heme affinity. The present invention further relates to novel mutations that reduce such heme loss.</p>			